These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36752890)

  • 1. Utility of public knowledge bases for the interpretation of comprehensive tumor molecular profiling results.
    Lebedeva A; Timokhin G; Ignatova E; Kavun A; Veselovsky E; Sharova M; Mileyko V; Yakushina V; Kuznetsova O; Stepanova M; Shilo P; Moiseenko F; Volkov N; Plaksa I; Isaev A; Gayryan M; Artemyeva E; Zhabina A; Kramchaninov M; Shamrikova V; Pokataev I; Rumyantsev A; Ledin E; Tryakin A; Fedyanin M; Ivanov M
    Clin Exp Med; 2023 Oct; 23(6):2663-2674. PubMed ID: 36752890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology.
    Martin-Romano P; Mezquita L; Hollebecque A; Lacroix L; Rouleau E; Gazzah A; Bahleda R; Planchard D; Varga A; Baldini C; Postel-Vinay S; Friboulet L; Loriot Y; Verlingue L; Geraud A; Camus MN; Nicotra C; Soria JC; André F; Besse B; Massard C; Italiano A
    JCO Precis Oncol; 2022 Oct; 6():e2100484. PubMed ID: 36315916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRAC (Clinical Relevance of Alterations in Cancer): a Knowledge Base for the Selection of Molecularly Matched Therapy for Solid Tumors.
    Lebedeva AA; Kavun AI; Veselovsky EM; Mileyko VA; Ivanov MV
    Sovrem Tekhnologii Med; 2022; 14(6):15-23. PubMed ID: 37181287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Analysis of Public Knowledge Bases for Precision Oncology.
    Pallarz S; Benary M; Lamping M; Rieke D; Starlinger J; Sers C; Wiegandt DL; Seibert M; Ševa J; Schäfer R; Keilholz U; Leser U
    JCO Precis Oncol; 2019; 3():. PubMed ID: 32914021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomically matched therapy in refractory colorectal cancer according to ESMO Scale for Clinical Actionability of Molecular Targets: experience of a comprehensive cancer centre network.
    Mulet Margalef N; Castillo C; Mosteiro M; Pérez X; Aguilar S; Ruíz-Pace F; Gil M; Cuadra C; Ruffinelli JC; Martínez M; Losa F; Soler G; Teulé À; Castany R; Gallego R; Ruíz A; Garralda E; Élez E; Vivancos A; Tabernero J; Salazar R; Dienstmann R; Santos Vivas C
    Mol Oncol; 2023 Sep; 17(9):1908-1916. PubMed ID: 37097008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma.
    Verdaguer H; Saurí T; Acosta DA; Guardiola M; Sierra A; Hernando J; Nuciforo P; Miquel JM; Molero C; Peiró S; Serra-Camprubí Q; Villacampa G; Aguilar S; Vivancos A; Tabernero J; Dienstmann R; Macarulla T
    Clin Cancer Res; 2022 Apr; 28(8):1662-1671. PubMed ID: 35042699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current practice of genomic profiling of patients with advanced solid tumours in Italy: the Italian Register of Actionable Mutations (RATIONAL) study.
    Normanno N; De Luca A; Abate RE; Morabito A; Milella M; Tabbò F; Curigliano G; Masini C; Marchetti P; Pruneri G; Guarneri V; Frassineti GL; Fasola G; Adamo V; Daniele B; Berardi R; Feroce F; Maiello E; Pinto C
    Eur J Cancer; 2023 Jul; 187():174-184. PubMed ID: 37167765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
    Mateo J; Chakravarty D; Dienstmann R; Jezdic S; Gonzalez-Perez A; Lopez-Bigas N; Ng CKY; Bedard PL; Tortora G; Douillard JY; Van Allen EM; Schultz N; Swanton C; André F; Pusztai L
    Ann Oncol; 2018 Sep; 29(9):1895-1902. PubMed ID: 30137196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Knowledge base toward understanding actionable alterations and realizing precision oncology.
    Takeuchi S; Okuda S
    Int J Clin Oncol; 2019 Feb; 24(2):123-130. PubMed ID: 30542800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness and real-world outcomes of next generation sequencing testing in patients with cancer: an observational study on the impact of selection based on clinical judgement.
    Colomer R; Miranda J; Romero-Laorden N; Hornedo J; González-Cortijo L; Mouron S; Bueno MJ; Mondéjar R; Quintela-Fandino M
    EClinicalMedicine; 2023 Jun; 60():102029. PubMed ID: 37304496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular tumour board at European Institute of Oncology: Report of the first three year activity of an Italian precision oncology experience.
    Repetto M; Crimini E; Boscolo Bielo L; Guerini-Rocco E; Ascione L; Bonfanti A; Zanzottera C; Mazzarella L; Ranghiero A; Belli C; Criscitiello C; Esposito A; Barberis MCP; Curigliano G
    Eur J Cancer; 2023 Apr; 183():79-89. PubMed ID: 36801623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular tests and target therapies in oncology: recommendations from the Italian workshop.
    Pinto C; Biffoni M; Popoli P; Marchetti A; Marchetti P; Martini N; Normanno N
    Future Oncol; 2021 Sep; 17(26):3529-3539. PubMed ID: 34254524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DrugCVar: a platform for evidence-based drug annotation for genetic variants in cancer.
    Zhang X; Qian Z; Wang Y; Zhang Q; Yu K; Zheng Y; Liu Z; Zhao Q; Liu ZX
    Bioinformatics; 2022 May; 38(11):3094-3098. PubMed ID: 35426945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liquid biopsy comprehensive genomic profiling of lung cancer in the Italian population: A real-world experience.
    Porta C; Pradelli L; Sicari E; Castellani S; Sivakumar S; Sokol E; Montesion M; Wieland T; Rambichler J; Minari R; Tiseo M
    Lung Cancer; 2023 Nov; 185():107359. PubMed ID: 37703610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Knowledge bases and software support for variant interpretation in precision oncology.
    Borchert F; Mock A; Tomczak A; Hügel J; Alkarkoukly S; Knurr A; Volckmar AL; Stenzinger A; Schirmacher P; Debus J; Jäger D; Longerich T; Fröhling S; Eils R; Bougatf N; Sax U; Schapranow MP
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 33971666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How to read a next-generation sequencing report-what oncologists need to know.
    Schmid S; Jochum W; Padberg B; Demmer I; Mertz KD; Joerger M; Britschgi C; Matter MS; Rothschild SI; Omlin A
    ESMO Open; 2022 Oct; 7(5):100570. PubMed ID: 36183443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Precision medicine in breast cancer: From clinical trials to clinical practice.
    Crimini E; Repetto M; Aftimos P; Botticelli A; Marchetti P; Curigliano G
    Cancer Treat Rev; 2021 Jul; 98():102223. PubMed ID: 34049187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets.
    Moreira A; Masliah-Planchon J; Callens C; Vacher S; Lecerf C; Frelaut M; Borcoman E; Torossian N; Ricci F; Hescot S; Sablin MP; Tresca P; Loirat D; Melaabi S; Trabelsi-Grati O; Pierron G; Gentien D; Bernard V; Vincent Salomon A; Servant N; Bieche I; Le Tourneau C; Kamal M
    Eur J Cancer; 2019 Nov; 121():202-209. PubMed ID: 31593830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OncoKB: A Precision Oncology Knowledge Base.
    Chakravarty D; Gao J; Phillips SM; Kundra R; Zhang H; Wang J; Rudolph JE; Yaeger R; Soumerai T; Nissan MH; Chang MT; Chandarlapaty S; Traina TA; Paik PK; Ho AL; Hantash FM; Grupe A; Baxi SS; Callahan MK; Snyder A; Chi P; Danila D; Gounder M; Harding JJ; Hellmann MD; Iyer G; Janjigian Y; Kaley T; Levine DA; Lowery M; Omuro A; Postow MA; Rathkopf D; Shoushtari AN; Shukla N; Voss M; Paraiso E; Zehir A; Berger MF; Taylor BS; Saltz LB; Riely GJ; Ladanyi M; Hyman DM; Baselga J; Sabbatini P; Solit DB; Schultz N
    JCO Precis Oncol; 2017 Jul; 2017():. PubMed ID: 28890946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SwissMTB: establishing comprehensive molecular cancer diagnostics in Swiss clinics.
    Singer F; Irmisch A; Toussaint NC; Grob L; Singer J; Thurnherr T; Beerenwinkel N; Levesque MP; Dummer R; Quagliata L; Rothschild SI; Wicki A; Beisel C; Stekhoven DJ
    BMC Med Inform Decis Mak; 2018 Oct; 18(1):89. PubMed ID: 30373609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.